Mereo BioPharma Group Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de Mereo BioPharma Group disminuyan a un ritmo anual de 0.1%, mientras que sus ingresos anuales crecerán a un ritmo de 55.9% por año. Se espera que el BPA crezca en un 56.4% al año.

Información clave

-0.1%

Tasa de crecimiento de los beneficios

56.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	42.4%
Tasa de crecimiento de los ingresos	55.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:MAH0 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	41	-29	-60	N/A	3
12/31/2025	16	-28	-10	N/A	5
12/31/2024	14	-24	N/A	N/A	5
9/30/2024	1	-45	-31	-30	N/A
6/30/2024	1	-37	-21	-20	N/A
3/31/2024	10	-26	-21	-20	N/A
12/31/2023	10	-29	-22	-21	N/A
9/30/2023	9	-31	-29	-28	N/A
6/30/2023	9	-32	-42	-42	N/A
3/31/2023	N/A	-42	-46	-46	N/A
12/31/2022	N/A	-42	-47	-49	N/A
9/30/2022	N/A	-31	-42	-43	N/A
6/30/2022	N/A	-23	-40	-41	N/A
3/31/2022	24	-4	-25	-26	N/A
12/31/2021	49	17	-8	-7	N/A
9/30/2021	49	-10	-9	-8	N/A
6/30/2021	50	-37	-10	-10	N/A
3/31/2021	25	-131	-23	-25	N/A
12/31/2020	N/A	-224	-36	-39	N/A
9/30/2020	N/A	-198	-35	-37	N/A
6/30/2020	N/A	-177	-34	-36	N/A
3/31/2020	N/A	-111	-46	-47	N/A
12/31/2019	N/A	-46	-61	-61	N/A
9/30/2019	N/A	-41	-50	-50	N/A
6/30/2019	N/A	-40	-45	-45	N/A
3/31/2019	N/A	-41	-38	-38	N/A
12/31/2018	N/A	-41	-30	-29	N/A
9/30/2018	N/A	-42	-41	-39	N/A
6/30/2018	N/A	-44	N/A	-48	N/A
3/31/2018	N/A	-50	N/A	-48	N/A
12/31/2017	N/A	-52	N/A	-43	N/A
9/30/2017	N/A	-50	N/A	-41	N/A
6/30/2017	N/A	-47	N/A	-39	N/A
3/31/2017	N/A	-41	N/A	-37	N/A
12/31/2016	N/A	-35	N/A	-37	N/A
6/30/2016	N/A	-39	N/A	-25	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MAH0 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MAH0 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MAH0 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (55.9% al año) de MAH0 crezcan más rápidamente que los del mercado German (5.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (55.9% al año) de MAH0 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MAH0 se prevé que sea elevada dentro de 3 años.

Mereo BioPharma Group Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Less than half of directors are independent

Less than half of directors are independent

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo Biopharma Group plc Announces Board Changes

Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan

Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors

Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Astrazeneca Reportedly Considering Take over Offer for Mereo

Rubric Capital Sends Letter to Mereo BioPharma

Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

Rubric Capital Discloses its Views on Mereo BioPharma

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors

The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease

Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Mereo BioPharma Group plc has completed a Follow-on Equity Offering in the amount of $100.05 million.

Mereo BioPharma Group plc, Annual General Meeting, Feb 01, 2021

Ultragenyx Pharmaceutical Inc. and Mereo Biopharma Group plc Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Mereo Biopharma Provides Update with Respect to the Cancellation of Admission of Its Ordinary Shares to Trading on Aim

Mereo Biopharma Group plc Announces the Appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, Effective December 7, 2020

Mereo BioPharma Group Plans Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

Mereo BioPharma Group plc Announces Changes to Board of Directors

Mereo Biopharma Group plc Receives U.S. Food and Drug Administration Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

Mereo BioPharma Group plc Announces Initiation of Placebo-Controlled Phase 1B/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento